Similar articles

• Nature of the anti-Xa activity induced by a heparin analogue (SSHA) in vivo.

  Schmitz-Huebner U, Lobreyer EM, van de Loo J. Schmitz-Huebner U, et al. Thromb Res. 1982 Sep 15;27(6):757-62. doi: 10.1016/0049-3848(82)90014-7. Thromb Res. 1982. PMID: 6817453 No abstract available.
• In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. II. Effects of a heparin analogue.

  Schmitz-Huebner U, Asbeck F, van de Loo J. Schmitz-Huebner U, et al. Thromb Haemost. 1981 Oct;46(3):617-20. Thromb Haemost. 1981. PMID: 6797091
• The anticoagulant properties of mast cell product, chondroitin sulphate E.

  Scully MF, Ellis V, Seno N, Kakkar VV. Scully MF, et al. Biochem Biophys Res Commun. 1986 May 29;137(1):15-22. doi: 10.1016/0006-291x(86)91169-1. Biochem Biophys Res Commun. 1986. PMID: 3087353
• Argatroban, a new treatment option for heparin-induced thrombocytopenia.

  Cleveland KW. Cleveland KW. Crit Care Nurse. 2003 Dec;23(6):61-6. Crit Care Nurse. 2003. PMID: 14692173 Review. No abstract available.
• Anticoagulation monitoring.

  Ng VL. Ng VL. Clin Lab Med. 2009 Jun;29(2):283-304. doi: 10.1016/j.cll.2009.05.003. Clin Lab Med. 2009. PMID: 19665679 Review.